Antitumor and Antimetastasis Activities of Heparin-based Micelle Served As Both Carrier and Drug

ACS Appl Mater Interfaces. 2016 Apr 20;8(15):9577-89. doi: 10.1021/acsami.5b12347. Epub 2016 Apr 8.

Abstract

Effective treatments for tumors are not easy to achieve due to the existence of metastases, which are responsible for most tumor death. Hence, a new drug delivery system is a pressing need, which should be biocompatible, stimuli-responsive, and multifunctional, including antitumor, antimetastasis, and antiangiogenesis effects. However, it is challenging to achieve all of these properties in one drug delivery system. Here, we developed a system of drug DOX and heparin into one self-assemble nanoparticle via pH-sensitive hydrazone bond and hydrophobic groups, deoxycholate. In the process, heparin itself was not only as the hydrophilic segments of the carrier, but also processed multiple biological functions such as antiangiogenesis and antimetastasis effect. The micelle nanoparticle HD-DOX processed good stability and acidic pH-triggered drug release property. After systemic administration, heparin-based micelle nanoparticle showed longer half-time and enhanced accumulation of DOX in tumors through the enhanced permeability and retention effect, leading to more efficient antitumor effects. In addition, heparin could hinder platelet-induced tumor cells epithelial-mesenchymal transition (EMT) and partially affect cell actin cytoskeletal arrangement, resulting in the disorganization of the actin cytoskeleton. Therefore, HD-DOX exhibited significant inhibitory effect on the metastasis in melanoma animal model in C57BL/6 mouse. Meanwhile, benefited from the antiangiogenesis effect of heparin, tube formations in endothelial cells were effectively inhibited and tumor vascular density was decreased by HD-DOX. Taken together, our study developed a self-assembly nanoplatform that both the drug and carrier had therapeutic effects with ideal antitumor efficacy.

Keywords: EMT; angiogenesis; heparin; metastasis; micelle.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actin Cytoskeleton / drug effects
  • Actin Cytoskeleton / metabolism
  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Blood Platelets / drug effects
  • Cell Death / drug effects
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Deoxycholic Acid / chemical synthesis
  • Deoxycholic Acid / chemistry
  • Doxorubicin / chemistry
  • Doxorubicin / pharmacokinetics
  • Doxorubicin / pharmacology
  • Doxorubicin / therapeutic use
  • Drug Carriers / chemistry*
  • Erythrocytes / drug effects
  • Hemolysis / drug effects
  • Heparin / chemical synthesis
  • Heparin / chemistry*
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Hydrodynamics
  • Injections, Intravenous
  • Mice, Inbred C57BL
  • Micelles*
  • Nanoparticles / chemistry
  • Neoplasm Metastasis / drug therapy*
  • Neovascularization, Physiologic / drug effects
  • Tissue Distribution / drug effects

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Drug Carriers
  • Micelles
  • Deoxycholic Acid
  • Doxorubicin
  • Heparin